How to Value CROs, CDMOs, and Life Sciences Tools Companies

Introduction

Valuing life sciences tools, CROs, and CDMOs requires a set of sub-sector-specific adjustments that go beyond standard healthcare valuation frameworks. While the core methodology remains EV/EBITDA-based comparable company analysis (unlike pharma, which uses sum-of-the-parts, or biotech, which uses rNPV), the adjustments needed to make companies comparable within each sub-sector are significant. A CRO reporting $10 billion in revenue with 30% pass-through costs is not comparable on revenue metrics to one reporting $5 billion with 10% pass-through. A CDMO running at 85% utilization is not comparable on EBITDA margins to one running at 60%. A tools company with 75% recurring revenue is not comparable on growth sustainability to one with 45%. Healthcare bankers must understand these nuances to build credible valuation analyses and advise on transactions effectively.

The Pass-Through Adjustment

The most critical adjustment in CRO valuation is removing pass-through revenue from all revenue-based metrics. Pass-through costs (investigator fees, lab costs, shipping) flow through the CRO's income statement at zero margin, inflating reported revenue without contributing to profitability.

The adjusted metrics tell a fundamentally different story about growth, margin quality, and relative valuation. Failing to make this adjustment is one of the most common analytical errors in CRO coverage, and interviewers at healthcare-focused banks will test for it.

FSO/FSP Mix Adjustment

A CRO's FSO/FSP mix directly affects its margin profile. FSO engagements generate mid-to-high teens EBITDA margins; FSP engagements generate high single digits to low teens. Two CROs with identical EBITDA margins but different FSO/FSP mixes are not equivalent: the one with higher FSP mix has more margin expansion potential if it shifts toward FSO, while the one with higher FSO mix has better near-term margin quality.

When building a CRO comp table, note each company's FSO/FSP revenue split (disclosed in annual filings or investor presentations) and account for it in your margin analysis. If a target CRO has an unusually high FSP mix relative to peers, its lower margins may represent an improvement opportunity for acquirers rather than a fundamental quality difference.

Backlog-Based Forward Metrics

Because CROs have multi-year contracted backlogs that provide 2-3 years of revenue visibility, forward valuation metrics carry more weight than in most healthcare sub-sectors. The book-to-bill ratio and backlog growth rate are the primary determinants of whether a CRO should trade at a premium or discount to peers.

Backlog-Adjusted Growth Rate

A forward-looking growth estimate derived from the CRO's backlog conversion rate and recent booking trends, rather than from analyst consensus estimates or historical growth extrapolation. If a CRO has $20 billion in backlog, a quarterly conversion rate of 10%, and a trailing book-to-bill of 1.25x, the implied forward growth rate can be calculated from the net backlog increase (new bookings minus recognized revenue minus cancellations). This metric is more reliable than consensus estimates for CROs because backlog provides a direct pipeline of contracted future revenue.

A CRO with accelerating book-to-bill (indicating growing demand) should trade at a premium to one with decelerating book-to-bill, even if their current EBITDA margins are identical. In practice, the market applies a 2-4 turn multiple premium to CROs with book-to-bill consistently above 1.2x.

Capacity Utilization: The Dominant Variable

CDMO margins are more sensitive to capacity utilization than to any other variable. Manufacturing facilities carry enormous fixed costs (depreciation, quality systems, compliance staff, facility maintenance), and the difference between 60% and 85% utilization can swing EBITDA margins by 10-15 percentage points. This makes capacity utilization the single most important variable in CDMO financial analysis and the primary adjustment needed for comparability.

Modality Mix and Growth Quality

Not all CDMO revenue is created equal. Revenue from small molecule manufacturing (commoditized, competitive, low growth) commands lower multiples than revenue from biologics manufacturing (higher barriers, faster growth). Revenue from specialty modalities (ADC conjugation, CGT viral vector production, peptide synthesis for GLP-1) commands the highest premiums because capacity is scarce and pricing power is strong.

For diversified CDMOs (like Catalent pre-acquisition or Lonza), a sum-of-the-parts approach using modality-specific multiples often produces a more accurate valuation than a single blended EV/EBITDA. This is especially true when one modality (such as GLP-1 peptide manufacturing) is growing at 20%+ while another (oral solid dose small molecule) is growing at 3-4%.

Commercial Status of Underlying Drug Programs

Revenue-by-Drug-Stage Analysis

A CDMO valuation technique that segments the CDMO's revenue by the development stage of the underlying drug programs: pre-clinical/Phase I, Phase II, Phase III, and commercial. Revenue from drugs that are already commercially marketed is the most valuable because it is effectively recurring (the drug needs to be manufactured continuously). Revenue from Phase III programs is moderately valuable (high probability of reaching commercial stage). Revenue from early-phase programs is the least valuable because there is meaningful risk that the drug will fail and the manufacturing contract will be cancelled. CDMOs with a high percentage of revenue from commercial-stage drugs trade at premium multiples relative to those dependent on clinical-stage programs.

The commercial status analysis is particularly important for smaller CDMOs that may derive 30-50% of their revenue from a handful of drug programs. If one of those programs fails in Phase III, the CDMO loses both the development revenue and the anticipated commercial manufacturing contract, potentially causing a 15-25% revenue decline. Diligencing the clinical status and probability of success for the CDMO's top 10 drug programs by revenue is essential for any acquisition analysis.

The BIOSECURE and Reshoring Premium

The BIOSECURE Act has introduced a new dimension to CDMO valuation: geographic supply chain positioning. Western CDMOs with capacity to absorb demand redirected from Chinese providers (primarily WuXi AppTec and WuXi Biologics) are commanding a strategic premium above what standalone financial analysis would justify. This premium reflects the scarcity of immediately available Western manufacturing capacity and the multi-year timeline required to build new facilities. Samsung Biologics, Lonza, FUJIFILM Diosynth, and Thermo Fisher's pharma services division are primary beneficiaries.

For healthcare bankers advising on CDMO transactions, the BIOSECURE reshoring dynamic creates a dual valuation framework. The standalone DCF or EV/EBITDA reflects the CDMO's financial fundamentals (current utilization, margins, growth). The strategic premium reflects the incremental value of Western manufacturing capacity in a supply-constrained environment. The gap between these two valuations can be significant: a CDMO that might trade at 14-16x EBITDA on standalone financials could command 18-22x in a strategic sale to a buyer seeking BIOSECURE-compliant capacity. This premium is analogous to the channel synergy premium that strategic pharma acquirers pay for biotech pipeline assets, except the "synergy" is supply chain security rather than commercial revenue.

Take-or-Pay Contracts and Revenue Quality

CDMO revenue quality varies significantly depending on contract structure. Take-or-pay contracts, where the customer commits to purchasing a minimum volume regardless of actual demand, provide the highest-quality revenue because payment is guaranteed even if the customer's drug sales decline. Contracts with minimum commitments (but not full take-or-pay) provide moderate security. Project-based contracts for development services are the lowest quality because they are finite and non-recurring. When valuing a CDMO, segmenting revenue by contract type and applying different growth and risk assumptions to each segment produces a more accurate valuation than treating all revenue equally.

The Recurring Revenue Premium

The most powerful predictor of tools company multiples is the percentage of revenue from recurring sources (consumables + service contracts). The market applies a clear, monotonic premium as recurring revenue percentage increases.

The DBS Premium

Danaher's involvement in tools M&A introduces a unique dynamic. Because of the Danaher Business System's proven track record of expanding acquired companies' margins by 500-1,000+ basis points over 3-5 years, Danaher can rationally pay 2-4 turns above what other acquirers can justify. Danaher's margin expansion capability effectively allows it to "create" EBITDA that does not yet exist, making the forward-looking multiple on DBS-improved economics comparable to what others pay on current economics.

This dynamic has two implications for healthcare bankers. First, any sell-side process for a tools company should include Danaher (or at least be positioned with Danaher's potential participation in mind). Second, when analyzing precedent transactions, deals involving Danaher as the acquirer should be flagged as potentially reflecting a DBS premium that other acquirers would not pay.

Installed Base Valuation

For tools companies with significant instrument installed bases, the installed base itself has quantifiable value beyond current-period revenue. Each installed instrument generates a stream of consumable and service revenue over its 7-15 year useful life. An instrument with a $50,000 purchase price may generate $200,000+ in lifetime consumable and service revenue through spec-in lock-in. Valuing the installed base involves estimating the remaining useful life of all deployed instruments, projecting the annual consumable and service revenue per instrument, and discounting the aggregate stream to present value.

This installed base valuation is particularly relevant in M&A because acquiring a tools company with 50,000 installed instruments is effectively acquiring a contracted revenue stream. The acquirer can cross-sell additional consumables and services through the installed base, driving revenue synergies that justify acquisition premiums. Thermo Fisher's acquisition strategy explicitly targets companies with large installed bases that can be leveraged for cross-selling, and this installed base logic is a primary valuation driver in most tools M&A transactions.

The Destocking Normalization

After the 2022-2024 destocking cycle, tools company valuation requires explicit normalization for the COVID demand distortion. Using 2021 peak revenue overstates the business; using 2023 trough revenue understates it. The most defensible approach is to:

1. Calculate the pre-COVID (2018-2019) organic growth CAGR 2. Project forward from 2019 at that organic rate to establish a "normalized" revenue trajectory 3. Compare the current revenue level to this normalized trajectory 4. If current revenue is below the normalized trajectory, the gap represents recovery upside; if above, it may reflect lingering over-ordering

This normalized revenue serves as the base for forward projections and, combined with normalized margins (excluding both pandemic-era surges and destocking-era compressions), produces the cleanest EBITDA base for valuation.

When building a life sciences tools/services comp table for a pitch or transaction, organize companies into sub-groups rather than lumping all tools companies together:

Within each sub-group, rank companies by the key differentiating metric (recurring revenue % for tools, book-to-bill for CROs, utilization for CDMOs) and explain why the target should trade at a premium, discount, or in line with the sub-group median.

The next article covers M&A and PE activity in life sciences tools and services, including the consolidation logic that has driven landmark transactions and the emerging CRDMO convergence trend.